These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 18955042)

  • 1. Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer.
    Narita M; Takei D; Shiokawa M; Tsurukawa Y; Matsushima Y; Nakamura A; Takagi S; Asato M; Ikegami D; Narita M; Amano T; Niikura K; Hashimoto K; Kuzumaki N; Suzuki T
    Eur J Pharmacol; 2008 Dec; 600(1-3):105-9. PubMed ID: 18955042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of the dopamine system-stabilizer aripiprazole for reducing morphine-induced emesis.
    Shiokawa M; Narita M; Nakamura A; Kurokawa K; Inoue T; Suzuki T
    Eur J Pharmacol; 2007 Sep; 570(1-3):108-10. PubMed ID: 17678644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperprolactinemia with aripiprazole: understanding the paradox.
    Saraf G; Behere RV; Venkatasubramanian G; Rao NP; Varambally S; Gangadhar BN
    Am J Ther; 2014; 21(3):e80-1. PubMed ID: 22357167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
    Li Z; Ichikawa J; Dai J; Meltzer HY
    Eur J Pharmacol; 2004 Jun; 493(1-3):75-83. PubMed ID: 15189766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
    Leite JV; Guimarães FS; Moreira FA
    Eur J Pharmacol; 2008 Jan; 578(2-3):222-7. PubMed ID: 18021764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antipsychotic aripiprazole selectively prevents the stimulant and rewarding effects of morphine in mice.
    Almeida-Santos AF; Gobira PH; Souza DP; Ferreira RC; Romero TR; Duarte ID; Aguiar DC; Moreira FA
    Eur J Pharmacol; 2014 Nov; 742():139-44. PubMed ID: 25218988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile.
    Hirose T; Uwahodo Y; Yamada S; Miwa T; Kikuchi T; Kitagawa H; Burris KD; Altar CA; Nabeshima T
    J Psychopharmacol; 2004 Sep; 18(3):375-83. PubMed ID: 15358981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
    Tadori Y; Forbes RA; McQuade RD; Kikuchi T
    Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects.
    Han M; Huang XF; Deng C
    Int J Neuropsychopharmacol; 2009 Aug; 12(7):941-52. PubMed ID: 19203411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tardive dyskinesia due to aripiprazole: report of 2 cases.
    Lungu C; Aia PG; Shih LC; Esper CD; Factor SA; Tarsy D
    J Clin Psychopharmacol; 2009 Apr; 29(2):185-6. PubMed ID: 19512985
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of amisulpride and aripiprazole on progressive-ratio schedule performance: comparison with clozapine and haloperidol.
    den Boon FS; Body S; Hampson CL; Bradshaw CM; Szabadi E; de Bruin N
    J Psychopharmacol; 2012 Sep; 26(9):1231-43. PubMed ID: 21969105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models.
    Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
    Int J Neuropsychopharmacol; 2011 Oct; 14(9):1165-78. PubMed ID: 21087552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Aripiprazole as "dopamine sensitivity stabilizer"].
    Tadokoro S
    Nihon Rinsho; 2013 Apr; 71(4):684-8. PubMed ID: 23678600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist.
    Ohno Y; Okano M; Imaki J; Tatara A; Okumura T; Shimizu S
    Pharmacol Biochem Behav; 2010 Aug; 96(2):175-80. PubMed ID: 20460137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aripiprazole's receptor pharmacology and extrapyramidal side effects.
    Poyurovsky M; Weizman R; Weizman A
    Am J Psychiatry; 2008 Mar; 165(3):398; author reply 398-9. PubMed ID: 18316435
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
    Oshiro Y; Sato S; Kurahashi N; Tanaka T; Kikuchi T; Tottori K; Uwahodo Y; Nishi T
    J Med Chem; 1998 Feb; 41(5):658-67. PubMed ID: 9513593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aripiprazole attenuates established behavioral sensitization induced by methamphetamine.
    Futamura T; Akiyama S; Sugino H; Forbes A; McQuade RD; Kikuchi T
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1115-9. PubMed ID: 20561555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective action of an atypical neuroleptic on the mechanisms related to the development of cocaine addiction: a pre-clinical behavioural study.
    Marinho EA; Oliveira-Lima AJ; Wuo-Silva R; Santos R; Baldaia MA; Hollais AW; Longo BM; Berro LF; Frussa-Filho R
    Int J Neuropsychopharmacol; 2014 Apr; 17(4):613-23. PubMed ID: 24345415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and bioactivity of aripiprazole derivatives.
    Ge HX; Wang LC; Jiang ZZ; Ni SL
    Arzneimittelforschung; 2006; 56(10):673-7. PubMed ID: 17225561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.